BioFuels Journal

Jupiter, FL—Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company with patented and proprietary technology used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, Oct. 1 announced the receipt of a $500,000 licensing payment from Abengoa Bioenergy for commercial scale production of Abengoa's proprietary cellulase enzymes, used for converting biomass into ethanol, developed under Abengoa's license agreement with Dyadic.

"We are very excited that our pioneering C1 technology platform is playing a pivotal part in the commercialization of cellulosic ethanol and the long-awaited realization and development of this important industry," said Mark Emalfarb, CEO of Dyadic International Inc.

Emalfarb added, "As part of their license agreement, Abengoa has developed their own proprietary cellulase enzymes using the C1 technology platform, and has now produced these enzymes at industrial scale. Abengoa is truly an industry leader, having developed a fully integrated process for creating cellulosic sugars from biomass.

"This is a landmark achievement for Dyadic in that Abengoa is the first licensee of the company's proven C1 technology to produce enzymes for a commercial scale, second-generation biofuel plant."

Under the terms of Dyadic's C1 licensing agreement with Abengoa, Dyadic will receive future royalty payments based on Abengoa's production of cellulosic ethanol at the Hugoton facility and future plants where Abengoa uses C1-derived enzymes in the processing of cellulosic sugars for the production of biofuels, biochemicals and other bio-based products.

For more information, call 561-743-8333.

See Related Websites/Articles:

• Dyadic International

more ADVANCED BIOFUELS...